Literature DB >> 11796345

Efficacy of ceftriaxone and gentamicin given once a day by using human-like pharmacokinetics in treatment of experimental staphylococcal endocarditis.

Joan Gavaldà1, Pedro López, Teresa Martín, Xavier Gomis, José Luis Ramírez, Carlos Azuaje, Benito Almirante, Albert Pahissa.   

Abstract

We compared the efficacy of ceftriaxone combined with gentamicin, both given once a day, with that of cloxacillin given every 4 h plus gentamicin given once a day or in three daily doses (t.i.d.) for the treatment of experimental methicillin-susceptible staphylococcal endocarditis. The antibiotics were administered by using human-like (H-L) pharmacokinetics that simulated the profiles of these drugs in human serum. Animals with catheter-induced endocarditis were infected intravenously with 10(5) CFU of Staphylococcus aureus S5 (MICs and minimal bactericidal concentrations of cloxacillin, ceftriaxone, and gentamicin, 0.5 and 2 microg/ml, 4 and 8 microg/ml, and 0.5 and 1 microg/ml, respectively). The animals were then treated for 24 h with cloxacillin at a dose of 2 g that simulated H-L pharmacokinetics (H-L 2 g) every 4 h alone or combined with gentamicin (administered at doses of H-L 1 mg/kg of body weight every 8 h or H-L 4.5 mg/kg every 24 h) or with ceftriaxone at H-L 2 g every 24 h alone or combined with gentamicin (administered at doses of H-L 1 mg/kg every 8 h or H-L 4.5 mg/kg every 24 h). The results of therapy for experimental endocarditis due to the S5 strain showed that (i) cloxacillin alone is more effective than ceftriaxone alone in reducing the bacterial load (P < 0.01), (ii) the combination of cloxacillin or ceftriaxone with gentamicin is more effective than each of these drugs alone (P < 0.01), and (iii) Ceftriaxone H-L plus gentamicin H-L 4.5 mg/kg, both administered every 24 h, showed efficacy similar to that of the "gold standard," cloxacillin H-L plus gentamicin H-L 1 mg/kg t.i.d. (P > 0.05). An increase in the interval of administration of gentamicin to once daily resulted in a reduction in the numbers of bacteria in the vegetations equivalent to that achieved with the recommended regimen of cloxacillin plus gentamicin t.i.d. in the treatment of experimental endocarditis due to methicillin-susceptible S. aureus. Ceftriaxone plus gentamicin, both administered once a day, may be useful for home-based therapy for selected cases of staphylococcal endocarditis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11796345      PMCID: PMC127055          DOI: 10.1128/AAC.46.2.378-384.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

1.  Therapy of experimental staphylococcal infection with antibiotic combinations.

Authors:  M E Campos; S Rabinovich; I M Smith
Journal:  J Lab Clin Med       Date:  1974-02

2.  Gentamicin disposition and tissue accumulation on multiple dosing.

Authors:  J J Schentag; W J Jusko; J W Vance; T J Cumbo; E Abrutyn; M DeLattre; L M Gerbracht
Journal:  J Pharmacokinet Biopharm       Date:  1977-12

3.  Pharmacodynamics of vancomycin and ampicillin alone and in combination with gentamicin once daily or thrice daily against Enterococcus faecalis in an in vitro infection model.

Authors:  H H Houlihan; D P Stokes; M J Rybak
Journal:  J Antimicrob Chemother       Date:  2000-07       Impact factor: 5.790

4.  Comparison of ceftazidime, cefuroxime and methicillin in the treatment of Staphylococcus aureus endocarditis in rabbits.

Authors:  A A McColm; D M Ryan; P Acred
Journal:  J Antimicrob Chemother       Date:  1984-10       Impact factor: 5.790

5.  Treatment of experimental Staphylococcus aureus endocarditis: comparison of cephalothin, cefazolin, and methicillin.

Authors:  J Carrizosa; J Santoro; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1978-01       Impact factor: 5.191

6.  Newer beta-lactam antibiotics in the treatment of experimental Staphylococcus aureus endocarditis.

Authors:  V K Dhawan; H Thadepalli; M K Maier; M Nayyar; M B Bansal; S K Chuah
Journal:  J Antimicrob Chemother       Date:  1984-08       Impact factor: 5.790

7.  Nafcillin-gentamicin synergism in experimental staphylococcal endocarditis.

Authors:  M A Sande; K B Courtney
Journal:  J Lab Clin Med       Date:  1976-07

8.  Pharmacokinetics of ceftriaxone in humans.

Authors:  I H Patel; S Chen; M Parsonnet; M R Hackman; M A Brooks; J Konikoff; S A Kaplan
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

9.  Staphylococcus aureus endocarditis. A review of 119 cases.

Authors:  F Espersen; N Frimodt-Møller
Journal:  Arch Intern Med       Date:  1986-06

10.  Effects of medium and inoculum variations on screening for high-level aminoglycoside resistance in Enterococcus faecalis.

Authors:  D F Sahm; C Torres
Journal:  J Clin Microbiol       Date:  1988-02       Impact factor: 5.948

View more
  4 in total

1.  Simulation of human gentamicin pharmacokinetics in an experimental Enterococcus faecalis endocarditis model.

Authors:  Laurent Dubé; Jocelyne Caillon; Christèle Gras-Le Guen; Cédric Jacqueline; Marie-France Kergueris; Jean-Claude Granry; Gilles Potel; Denis Bugnon
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

2.  Determination of an inoculum effect with various cephalosporins among clinical isolates of methicillin-susceptible Staphylococcus aureus.

Authors:  Esteban C Nannini; Martin E Stryjewski; Kavindra V Singh; Tom H Rude; G Ralph Corey; Vance G Fowler; Barbara E Murray
Journal:  Antimicrob Agents Chemother       Date:  2010-03-08       Impact factor: 5.191

3.  Community-onset bacteraemia of unknown origin: clinical characteristics, epidemiology and outcome.

Authors:  C Hernandez; N Cobos-Trigueros; C Feher; L Morata; C De La Calle; F Marco; M Almela; A Soriano; J Mensa; A Del Rio; J A Martinez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-06-08       Impact factor: 3.267

4.  Once-daily gentamicin administration for community-associated methicillin resistant Staphylococcus aureus in an in vitro pharmacodynamic model: preliminary reports for the advantages for optimizing pharmacodynamic index.

Authors:  Sun Woo Kim; Dong-Gun Lee; Su-Mi Choi; Chulmin Park; Jae-Cheol Kwon; Si-Hyun Kim; Sun Hee Park; Jung-Hyun Choi; Jin-Hong Yoo; Wan-Shik Shin
Journal:  Yonsei Med J       Date:  2010-09       Impact factor: 2.759

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.